Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

15 results about "Mycobacterium sp" patented technology

Mycobacterium sp. Mycobacterium is a genus of Actinobacteria, given its own family, the Mycobacteriaceae. The genus includes pathogens known to cause serious diseases in mammals, including tuberculosis (Mycobacterium tuberculosis) and leprosy (Mycobacterium leprae).

Mycobacterium and method for degrading alkane organic pollutants

The invention relates to the technical field of organic pollutant degradation, and discloses a mycobacterium and a method for degrading alkane organic pollutants. The Mycobacterium sp. Is named as SLQ-1, the Mycobacterium sp. Is preserved in the China Center for Type Culture Collection on January 15, 2024, and the preservation number is CCTCC No: M 2024107. The Mycobacterium sp. Is named as SLQ-1, and the Mycobacterium sp. Has been preserved in the China Center for Type Culture Collection on January 15, 2024. The mycobacterium can effectively degrade alkane organic pollutants, especially organic pollutants below C8, SLQ-1 can grow and breed with 3-methylpentane as a carbon source and an energy source, 3-methylpentane is efficiently degraded, and the mycobacterium can adapt to a wide temperature range and a wide pH range (the degradation rate of 3-methylpentane can reach 99% or above when the pH is 6-8 and the temperature is 30-40). In addition, the mycobacterium SLQ-1 can also take 2-methylpentane, n-hexane, n-pentane and 2-methylbutane as a carbon source and an energy source, and can efficiently degrade the 2-methylpentane, the n-hexane, the n-pentane and the 2-methylbutane.
Owner:CHINA PETROLEUM & CHEMICAL CORP +1

Transaminase mutant and application thereof in chiral amine synthesis

The invention provides a transaminase mutant and application of the transaminase mutant in chiral amine synthesis. According to the transaminase derived from Mycobacterium sp. Provided by the invention, in a 1 mL reaction system for catalyzing N-Boc-3-piperidone to generate N-Boc-3-aminopiperidine, the 24-hour conversion rate is 95%, and the e.e. Value of the product is greater than 99%. On the basis, the invention further provides a series of mutants of the transaminase, the relative enzyme activity of the mutants reaches 153%-293%, and the catalytic activity of the transaminase is further improved. Wherein the 34-hour conversion rate of the optimal transaminase mutant is increased to 90% or above under the condition of 120g / L substrate concentration in a 10mL reaction system, and the e.e. Value of the product is greater than 99%. The production technology has the advantages of high catalytic activity, easiness in fermentation, environment friendliness and the like, and has good development and application values.
Owner:ZHEJIANG UNIV OF TECH

Candidatus liberibacter asiaticum and a method for detecting the same

The application discloses a mycobacterium maltose transferase Co GlgE and an encoding gene and application thereof.The maltose transferase Co The amino acid sequence of the GlgE is shown as SEQ ID NO.1.The application discloses a maltose transferase Corallococcus derived from mycobacterium sp.EGB Co GlgE, which can disperse maltoligosaccharide with a polymerization degree (DP) X into products with a DP of X ± 2n (X ≥ 3). Co The GlgE has glycosylation modification effects on alpha-arbutin and beta-arbutin, the biological activity of the modified arbutin is significantly improved, and the application value of the arbutin as an additive of whitening skin care products is improved.
Owner:NANJING AGRICULTURAL UNIVERSITY

Antibacterial or antifungal composition and pharmaceutical composition for preventing or treating bacterial or fungal infections, comprising VLX600

The present invention relates to an antibacterial or antifungal composition and a pharmaceutical composition for preventing or treating bacterial or fungal infections, both comprising VLX600. The antibacterial composition comprising VLX600 according to one aspect of the present invention exhibits antibacterial or antifungal activity against a wide range of strains, including Mycobacterium spp., Escherichia spp., Pseudomonas spp., Staphylococcus spp., Acinetobacter spp., Candida spp., and the like. The pharmaceutical composition comprising VLX600 demonstrates excellent antibacterial, antifungal, and therapeutic efficacy against pathogens and can be effectively utilized for the prevention or treatment of bacterial or fungal infections. Furthermore, VLX600 exhibits a synergistic effect with conventional antibiotics and thus is effective in treating infections caused by antibiotic-resistant bacterial strains.
Owner:SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Mycobacterium sp. based on various carbon-nitrogen metabolic pathways, method for isolating same, and use thereof

Provided are a Mycobacterium sp., a method for isolating same, and use thereof. The preservation number of the Mycobacterium sp. is CGMCC No. 21272 or CGMCC No. 21273. The Mycobacteria sp. has significant nitrogen fixation, carbon fixation, and ammonia oxidation capacity, can directly oxidize ammonia nitrogen into nitrogen, and has an antagonistic effect on other microorganisms.
Owner:PENG GUANGHAO

Oligonucleotide for identifying genus mycobacterium and application of the same

To provide a useful method for detecting the genus Mycobacterium acid-fast bacterium species.SOLUTION: A method for detecting the genus Mycobacterium acid-fast bacterium species that can be included in a sample includes amplifying a plurality of nucleic acid regions derived from a multicopy gene of the genus Mycobacterium acid-fast bacterium species, and the multicopy gene has the following characteristics (a) and / or (b): (a) the sequence identity of the genus Mycobacterium acid-fast bacterium species of a detection target between each strain is 82% or more, and the sequence identity between the genus Mycobacterium acid-fast bacterium species of a detection target and the other genus Mycobacterium acid-fast bacterium species is less than 82%; and (b) a multicopy gene is present in more than 98% of strains of the genus Mycobacterium acid-fast bacterium species of a detection target.SELECTED DRAWING: None
Owner:TOYOBO CO LTD +1

Combinations of pyridine thiolate oxide compounds and cystic fibrosis transmembrane conductance regulator modulators for use in the treatment of lung infections in subjects with cystic fibrosis

The present invention relates to a combination therapy for treating infections caused by bacteria of the genus Mycobacterium and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulator compounds.
Owner:UNIV DE ZARAGOZA +3

Pesticidal compositions comprising a thiazolidine and a biological agent

PCT designated stageWO2026024726A1BiocideAnimal repellantsMetarhizium speciesPseudomonas species
Owner:CORTEVA AGRISCIENCE LLC

Construction method and application of perillyl alcohol production strain

The invention discloses a construction method of a perillyl alcohol production strain and application of the perillyl alcohol production strain. The construction method comprises the following steps: transferring a plasmid pESKKDI carrying a mevalonic acid pathway, and a plasmid pNLsP450Fdx carrying a tomato Solanum lypersicum sourced NPP synthetase, a lemon Citrus limon sourced gene Ls and a Mycobacterium sp gene P450 gene into a gene knockout defective bacterium delta YqhD of wild type escherichia coli BL21 (DE3); the obtained perillyl alcohol production strain is used for production of perillyl alcohol, the yield of perillyl alcohol is improved and generation of a by-product perillyl aldehyde is reduced by further over-expressing electron transfer protein (Fdx) and optimizing the concentration of initial glucose in a fermentation culture medium, and a favorable guidance direction is provided for production of perillyl alcohol by escherichia coli.
Owner:JIANGNAN UNIV

A salt-tolerant triethylamine-degrading bacterial strain and its agent and its application in chemical wastewater treatment

The present invention discloses a salt-resistant triethylamine-degrading bacterial strain and its bacterial agent and its application in chemical wastewater treatment. The bacterial strain is Mycobacterium ( Mycobacterium sp. ), classified as Mycobacterium sp. CY-1, deposited in China Center for Type Culture Collection on April 16, 2025, with the deposit number: CCTCC NO: M 2025797. The strain of the present invention Mycobacterium sp. CY‑1 can use triethylamine as the sole carbon and nitrogen source to degrade triethylamine, and can achieve efficient degradation of high-concentration triethylamine in a high-salt environment with excellent degradation efficiency.
Owner:NANJING AGRICULTURAL UNIVERSITY

A compound microbial agent for controlling soil-borne diseases in farmland based on endophytic bacteria and its preparation method

PendingCN122081112AEfficient and comprehensive disease prevention and controlReduce the incidence of Fusarium wiltBiocideFungiBiotechnologyMicrobial agent
This invention relates to the field of microbial inoculants, and particularly to a compound inoculant for controlling soil-borne diseases in farmland based on endophytic bacteria, and its preparation method. The compound inoculant is composed of a main inoculant, auxiliary inoculants, and a fungicide. The main inoculant includes *Talaromyces sp. strain HBUM07170*, *Rhizobium sp. NXC24*, and *Methylobacterium brachiatum*, while the auxiliary inoculants include *Mycobacterium sp.*, *Caulobacter sp.*, *Penicillium sp.*, and *Pyronema omphalodes*, with each strain having a concentration of not less than 10%. 8 The concentration of CFU / ml is 1:1 (main bacterial agent mixture to auxiliary bacterial agent mixture), and tebuconazole is used as the fungicide. During preparation, each bacterial strain is activated and cultured separately, then mixed according to the specified volume ratio before adding tebuconazole and stirring to dissolve. This invention's compound bacterial agent exhibits synergistic effects among the bacterial strains, effectively antagonizing Fusarium oxysporum, reducing the incidence and mortality of lily wilt, and promoting plant growth. It combines biological control with chemical-assisted antibacterial effects and can be used in the preparation of control formulations for soil-borne diseases in farmland and lily wilt.
Owner:INSTITUTE OF SUBTROPICAL AGRICULTURE CHINESE ACADEMY OF SCIENCES

Method for synchronously converting hydrogen sulfide and sulfate radicals into elemental sulfur and sulfur-containing amino acid

The invention provides a method for synchronously converting hydrogen sulfide and sulfate radicals into elemental sulfur and sulfur-containing amino acid. The method comprises the following steps: in an aerobic state, pH value is lt; the method comprises the following steps: under the conditions that the concentration of sulfur ions is greater than or equal to 1.5 and the concentration of SO4 < 2-> is greater than or equal to 2g / L, enriching microbial florae containing mycobacteria, so that the oxidation reaction of hydrogen sulfide and the reduction reaction of sulfate radicals are synchronously carried out to obtain elemental sulfur and sulfur-containing amino acid. According to the method, two metabolic pathways of sulfur oxidation and sulfate reduction are ingeniously combined, efficient utilization and resource recycling of sulfur elements in hydrogen sulfide gas and sulfate wastewater are achieved through microbial flora containing mycobacteria, and an innovative, efficient and environment-friendly solution is provided for high-value recycling of sulfur-containing waste; and a new way is opened up for the application of the biotechnology in the treatment of extreme industrial wastes.
Owner:TSINGHUA UNIVERSITY

Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and / or diagnosis of tuberculosis infections.
Owner:ACCESS TO ADVANCED HEALTH INST

Application of novel cyclic peptide compound in anti-mycobacterium medicine

PendingCN121159641AAntibacterial agentsPeptidesCyclic peptideIsoniazid
The invention discloses a novel cyclic peptide compound. The structure of the novel cyclic peptide compound is shown as a formula (I). The compound has a remarkable inhibition effect on mycobacterium tuberculosis and mycobacterium marinum, is equivalent to a first-line drug isoniazide, and can generate a synergistic or additive effect when being combined with clinically common antibiotics. The invention also discloses application of a pharmaceutical composition containing the compound in preparation of medicines for treating and / or preventing mycobacterium infection diseases.
Owner:OCEAN UNIV OF CHINA